Yoram Nevo

Tel Aviv University — Israel

Biochemistry, Genetics and Molecular Biology · Life Sciences

33h-index5.3kcitations130works17.62yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Muscle Physiology and Disorders(60), Neurogenetic and Muscular Disorders Research(16), Peripheral Neuropathies and Disorders(13), Hereditary Neurological Disorders(11), RNA Research and Splicing(10)

Publications127 total

Exposure-response of serum biomarkers to vamorolone, a dissociative corticosteroidal anti-inflammatory drug, in 4- to <7-year children
Steroids·2025Open Access
Circulating protein biomarkers identified in two independent clinical trial cohorts of glucocorticoid-naive Duchenne muscular dystrophy patients.
Scientific Reports·2025· 1 citedOpen Access
684VPEfficacy of givinostat by age (6–7 and >7 years): a post hoc analysis of EPIDYS
Neuromuscular Disorders·2025
Long‐Term Evaluation of Givinostat in Duchenne Muscular Dystrophy, and Natural History Comparisons
Annals of Clinical and Translational Neurology·2025· 3 citedOpen Access
Inflammatory Neuropathies
Elsevier eBooks·2025
Short term and long term safety profile of Givinostat in Duchenne Muscular Dystrophy
Nervenheilkunde·2025
A rare homozygous <i>CAPN3</i> variant with distinct clinical features in unrelated families of Iraqi Jewish descent
Journal of Neuromuscular Diseases·2024Open Access
Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Neurology·2024· 100 cited
Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy
Neurology·2024· 54 citedOpen Access
Pulmonary function tests for evaluating the severity of Duchenne muscular dystrophy disease
Acta Paediatrica·2023· 7 citedOpen Access
Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy
JAMA Neurology·2022· 107 citedOpen Access
Clinical improvement of a toddler with COVID-19 focal cerebral arteriopathy possibly due to intra-arterial nimodipine
European Journal of Paediatric Neurology·2022· 1 citedOpen Access
Mutant C. elegans mitofusin leads to selective removal of mtDNA heteroplasmic deletions across generations to maintain fitness
BMC Biology·2022· 26 citedOpen Access
Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy
JAMA Network Open·2022· 79 citedOpen Access
Additional file 2 of Mutant C. elegans mitofusin leads to selective removal of mtDNA heteroplasmic deletions across generations to maintain fitness
Figshare·2022Open Access
Peak Cough Flow Reliability Versus Other Pulmonary Function Tests in Children with Duchenne Muscular Dystrophy
SSRN Electronic Journal·2022Open Access
Biallelic truncating variants in the muscular A‐type lamin‐interacting protein (<i>MLIP</i>) gene cause myopathy with hyperCKemia
European Journal of Neurology·2021· 6 cited
Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients
Journal of Comparative Effectiveness Research·2021· 58 citedOpen Access
Meta-analyses of deflazacort versus prednisone/prednisolone in patients with nonsense mutation Duchenne muscular dystrophy
Journal of Comparative Effectiveness Research·2021· 15 citedOpen Access
DMD - TREATMENT
Neuromuscular Disorders·2021
page 1 of 7Next →

Frequent Co-authors

Craig M. McDonald(19), Monique M. Ryan(17), Paula R. Clemens(16), Jean K. Mah(16), M. Tulinius(16), Anne M. Connolly(13), Eric P. Hoffman(12), Erik Henricson(11), Richard Webster(11), Nancy L. Kuntz(11), Avital Cnaan(10), Heather Gordish‐Dressman(10), Lauren P. Morgenroth(10), Richard S. Finkel(10), Alan Pestronk(9), Michela Guglieri(9), Richard T. Abresch(8), Tina Duong(8), Andrew J. Kornberg(8), Laura McAdam(7)